HUMA Therapeutics

Huma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management platform - New York and London (ots/PRNewswire) – – Class II clearance expands the patient population that can be managed – Companies working with Huma's platform can now launch algorithm innovations more quickly in a compliant and de-risked manner, democratising digital health innovation across the industry – Clearance was granted through the FDA's joint eSTAR programme which […]